With 0.9 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.96 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $4.5208 whereas the lowest price it dropped to was $4.15. The 52-week range on CRDF shows that it touched its highest point at $6.42 and its lowest point at $1.41 during that stretch. It currently has a 1-year price target of $11.00. Beta for the stock currently stands at 1.82.
Price Performance and Earnings:
Three-month performance surged to 59.55% while six-month performance rose 107.80%. The stock gained 193.79% in the past year, while it has gained 187.84% so far this year. A look at the trailing 12-month EPS for CRDF yields -0.95 with Next year EPS estimates of -0.98. For the next quarter, that number is -0.25. This implies an EPS growth rate of -6.21% for this year and 0.95% for next year.
Float and Shares Shorts:
At present, 66.52 million CRDF shares are outstanding with a float of 61.33 million shares on hand for trading. On 2024-12-13, short shares totaled 9.95 million, which was 1495.0 higher than short shares on 1731628800. In addition to Dr. Mark Erlander Ph.D. as the firm’s CEO & Director, Mr. James E. Levine serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 0.27657 of CRDF’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, CRDF reported revenue of $165000.0 and operating income of -$12601000.0. The EBITDA in the recently reported quarter was -$12500000.0 and diluted EPS was -$0.25.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CRDF since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With CRDF analysts setting a high price target of 13.0 and a low target of 10.0, the average target price over the next 12 months is 10.75. Based on these targets, CRDF could surge 205.16% to reach the target high and rise by 134.74% to reach the target low. Reaching the average price target will result in a growth of 152.35% from current levels.
Analysts have provided yearly estimates in a range of -$0.92788 being high and -$1.02765 being low. For CRDF, this leads to a yearly average estimate of -$0.98774. Based on analyst estimates, the high estimate for the next quarter is -$0.21 and the low estimate is -$0.31. The average estimate for the next quarter is thus -$0.25.
